Table 1.
Baseline and follow-up data.
Figure 1.
5-year cumulative probability of HBsAg seroclearance (a) and seroconversion (b) in HBV/HCV dually infected patients.
Fifteen patients had HBsAg seroclearance during the follow-up period with a 5-year cumulative incidence of 25.6% (a). HBsAg seroconversion was found in 5 of the 81 patients. The 5-year cumulative incidence was 8.3% (b). HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus.
Figure 2.
5-year cumulative probability of HBsAg seroclearance was significantly associated with LC and HBV DNA.
Using the Kaplan-Meier method, the 5-year cumulative probability of HBsAg seroclearance was significantly associated with LC (P = 0.007), baseline HBV DNA negativity (P = 0.012) and HBV DNA negativity 1 year after EOT (P = 0.000). HBsAg, hepatitis B surface antigen; LC, liver cirrhosis; HBV, hepatitis B virus; EOT, end of treatment.
Table 2.
Comparison of baseline and follow-up factors in HBV/HCV dually infected patients who did versus did not achieve HBsAg seroclearance.
Figure 3.
Cumulative probability of early HBsAg seroclearance was significantly associated with LC and HBV DNA.
Using Kaplan-Meier method, the cumulative probability of early HBsAg seroclearance remained significantly associated with LC, HBV DNA negativity at baseline and 6 months after EOT (P = 0.001, 0.016, 0.023). HBsAg, hepatitis B surface antigen; LC, liver cirrhosis; HBV, hepatitis B virus; EOT, end of treatment.
Table 3.
Comparison of baseline and follow-up factors of HBV/HCV dually infected patients who did versus did not achieve early/late HBsAg seroclearance.
Figure 4.
Cumulative probability of late HBsAg seroclearance was significantly associated with HBV DNA.
Using Kaplan-Meier method, the cumulative probability of late HBsAg seroclearance was significantly associated with HBV DNA negativity 1 year after EOT (P = 0.001). HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; EOT, end of treatment.
Table 4.
Comparison of baseline and follow-up factors in HBV/HCV dually infected patients who did achieve HBsAg seroconversion versus HBsAg seroclearance without seroconversion and non-HBsAg seroclearance.